PURPOSE: Prospectively identifying who will benefit from adjuvant chemotherapy (ACT) would improve clinical decisions for non-small cell lung cancer (NSCLC) patients. In this study, we aim to develop and validate a functional gene set that predicts the clinical benefits of ACT in NSCLC. EXPERIMENTAL DESIGN: An 18-hub-gene prognosis signature was developed through a systems biology approach, and its prognostic value was evaluated in six independent cohorts. The 18-hub-gene set was then integrated with genome-wide functional (RNAi) data and genetic aberration data to derive a 12-gene predictive signature for ACT benefits in NSCLC. RESULTS: Using a cohort of 442 stage I to III NSCLC patients who underwent surgical resection, we identified an 18-hub-gene set that robustly predicted the prognosis of patients with adenocarcinoma in all validation datasets across four microarray platforms. The hub genes, identified through a purely data-driven approach, have significant biological implications in tumor pathogenesis, including NKX2-1, Aurora Kinase A, PRC1, CDKN3, MBIP, and RRM2. The 12-gene predictive signature was successfully validated in two independent datasets (n = 90 and 176). The predicted benefit group showed significant improvement in survival after ACT (UT Lung SPORE data: HR = 0.34, P = 0.017; JBR.10 clinical trial data: HR = 0.36, P = 0.038), whereas the predicted nonbenefit group showed no survival benefit for 2 datasets (HR = 0.80, P = 0.70; HR = 0.91, P = 0.82). CONCLUSIONS: This is the first study to integrate genetic aberration, genome-wide RNAi data, and mRNA expression data to identify a functional gene set that predicts which resectable patients with non-small cell lung cancer will have a survival benefit with ACT.
PURPOSE: Prospectively identifying who will benefit from adjuvant chemotherapy (ACT) would improve clinical decisions for non-small cell lung cancer (NSCLC) patients. In this study, we aim to develop and validate a functional gene set that predicts the clinical benefits of ACT in NSCLC. EXPERIMENTAL DESIGN: An 18-hub-gene prognosis signature was developed through a systems biology approach, and its prognostic value was evaluated in six independent cohorts. The 18-hub-gene set was then integrated with genome-wide functional (RNAi) data and genetic aberration data to derive a 12-gene predictive signature for ACT benefits in NSCLC. RESULTS: Using a cohort of 442 stage I to III NSCLCpatients who underwent surgical resection, we identified an 18-hub-gene set that robustly predicted the prognosis of patients with adenocarcinoma in all validation datasets across four microarray platforms. The hub genes, identified through a purely data-driven approach, have significant biological implications in tumor pathogenesis, including NKX2-1, Aurora Kinase A, PRC1, CDKN3, MBIP, and RRM2. The 12-gene predictive signature was successfully validated in two independent datasets (n = 90 and 176). The predicted benefit group showed significant improvement in survival after ACT (UT Lung SPORE data: HR = 0.34, P = 0.017; JBR.10 clinical trial data: HR = 0.36, P = 0.038), whereas the predicted nonbenefit group showed no survival benefit for 2 datasets (HR = 0.80, P = 0.70; HR = 0.91, P = 0.82). CONCLUSIONS: This is the first study to integrate genetic aberration, genome-wide RNAi data, and mRNA expression data to identify a functional gene set that predicts which resectable patients with non-small cell lung cancer will have a survival benefit with ACT.
Authors: Dennis A Wigle; Igor Jurisica; Niki Radulovich; Melania Pintilie; Janet Rossant; Ni Liu; Chao Lu; James Woodgett; Isolde Seiden; Michael Johnston; Shaf Keshavjee; Gail Darling; Timothy Winton; Bobby-Joe Breitkreutz; Paul Jorgenson; Mike Tyers; Frances A Shepherd; Ming Sound Tsao Journal: Cancer Res Date: 2002-06-01 Impact factor: 12.701
Authors: Chang-Qi Zhu; Keyue Ding; Dan Strumpf; Barbara A Weir; Matthew Meyerson; Nathan Pennell; Roman K Thomas; Katsuhiko Naoki; Christine Ladd-Acosta; Ni Liu; Melania Pintilie; Sandy Der; Lesley Seymour; Igor Jurisica; Frances A Shepherd; Ming-Sound Tsao Journal: J Clin Oncol Date: 2010-09-07 Impact factor: 44.544
Authors: Yan Lu; William Lemon; Peng-Yuan Liu; Yijun Yi; Carl Morrison; Ping Yang; Zhifu Sun; Janos Szoke; William L Gerald; Mark Watson; Ramaswamy Govindan; Ming You Journal: PLoS Med Date: 2006-12 Impact factor: 11.069
Authors: Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons Journal: Clin Cancer Res Date: 2016-02-05 Impact factor: 12.531
Authors: Robert J G Cardnell; Carmen Behrens; Lixia Diao; YouHong Fan; Ximing Tang; Pan Tong; John D Minna; Gordon B Mills; John V Heymach; Ignacio I Wistuba; Jing Wang; Lauren A Byers Journal: Clin Cancer Res Date: 2015-04-15 Impact factor: 12.531
Authors: Yulong Chen; Masahiko Terajima; Yanan Yang; Li Sun; Young-Ho Ahn; Daniela Pankova; Daniel S Puperi; Takeshi Watanabe; Min P Kim; Shanda H Blackmon; Jaime Rodriguez; Hui Liu; Carmen Behrens; Ignacio I Wistuba; Rosalba Minelli; Kenneth L Scott; Johannah Sanchez-Adams; Farshid Guilak; Debananda Pati; Nishan Thilaganathan; Alan R Burns; Chad J Creighton; Elisabeth D Martinez; Tomasz Zal; K Jane Grande-Allen; Mitsuo Yamauchi; Jonathan M Kurie Journal: J Clin Invest Date: 2015-02-09 Impact factor: 14.808
Authors: Tina Cascone; Jodi A McKenzie; Rina M Mbofung; Simone Punt; Zhe Wang; Chunyu Xu; Leila J Williams; Zhiqiang Wang; Christopher A Bristow; Alessandro Carugo; Michael D Peoples; Lerong Li; Tatiana Karpinets; Lu Huang; Shruti Malu; Caitlin Creasy; Sara E Leahey; Jiong Chen; Yuan Chen; Helen Pelicano; Chantale Bernatchez; Y N Vashisht Gopal; Timothy P Heffernan; Jianhua Hu; Jing Wang; Rodabe N Amaria; Levi A Garraway; Peng Huang; Peiying Yang; Ignacio I Wistuba; Scott E Woodman; Jason Roszik; R Eric Davis; Michael A Davies; John V Heymach; Patrick Hwu; Weiyi Peng Journal: Cell Metab Date: 2018-04-05 Impact factor: 27.287
Authors: Yanan Yang; Young-Ho Ahn; Yulong Chen; Xiaochao Tan; Lixia Guo; Don L Gibbons; Christin Ungewiss; David H Peng; Xin Liu; Steven H Lin; Nishan Thilaganathan; Ignacio I Wistuba; Jaime Rodriguez-Canales; Georgia McLendon; Chad J Creighton; Jonathan M Kurie Journal: J Clin Invest Date: 2014-04-24 Impact factor: 14.808
Authors: Yang Xie; Wei Lu; Shidan Wang; Ximing Tang; Hao Tang; Yunyun Zhou; Cesar Moran; Carmen Behrens; Jack A Roth; Qinghua Zhou; David H Johnson; Stephen G Swisher; John V Heymach; Vassiliki A Papadimitrakopoulou; Guanghua Xiao; John D Minna; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2018-10-04 Impact factor: 12.531